Overview

Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Rifamycin SV MMX is a safe and effective treatment for Traveler's Diarrhea.
Phase:
Phase 3
Details
Lead Sponsor:
Cosmo Technologies Ltd
Valeant Pharmaceuticals International, Inc.
Collaborator:
Bausch Health Americas, Inc.
Treatments:
Rifamycin SV
Rifamycins